Session handouts and meetings archive

Handouts ... 2025 Innovation Academy, Chicago, IL, July 10-13 2025 Annual Meeting, Orlando, FL, March 7-11 2024 Innovation Academy, Seattle, WA, August 1-4 2024 Annual Meeting, San Diego, CA, March 8-12 2023 Innovation Academy, Tampa, FL, August 10-13 2023 Annual Meeting, New Orleans, LA, March 17-21 Sessions ... 2025 Innovation

CME & session evaluation archive

Claim CME & submit session evaluations ... Claim CME credit and submit session evaluations for attending previous Academy meetings: ... 2025 Innovation Academy, Chicago, IL, July 10-13 2025 Annual Meeting, Orlando, FL, March 7-11 2024 Innovation Academy, Seattle, WA, August 1-4 2024 Annual Meeting, San Diego, CA, March 8-12 2023

AADA hosts largest Capitol Hill skin cancer check in a decade

On May 15, the AADA hosted its 10th annual Capitol Hill Skin Cancer Check and Health Fair with the Congressional Skin Cancer Caucus. This event was our largest to date, hosting 198 Hill staffers and 11 members of Congress, performing 127 skin checks, and providing 75 Reveal camera image results.

Key messages to communicate about Indoor tanning

Key messages ... Using indoor tanning beds can increase your risk of skin cancer, including melanoma, the deadliest form of skin cancer. (1-15) ... Using tanning beds before age 20 can increase your chances of developing melanoma by 47%, and the risk increases with each use. (16) ... Women younger

PDF of Nominating Committee Member Rep. Regional Map

the PE WEST REGION OF THE UNITED STATES QC ON AND CANADIAN PROVINCES ONLY NS (Shown in Pink) ND WA

PDF of Board of Directors Regional Map

NL 9 BC 40 NL AB SK MB 9 47 4 12 PE QC 1 ON 64 NS 140 20 WA ND MT NB 333 46 22

Academy physician leaders meet with federal legislators

On June 4, AADA physician leaders met with legislators in Washington, D.C., as part of the House Call on the Mall fundraiser hosted by the National Republican Congressional Committee and Rep. John Joyce, MD, FAAD (R-PA). During the event, AADA leaders reiterated the importance of Medicare physician payment reform. ...

2025 AAD Innovation Academy Attendee Statistics

Innovation Academy Attendance over the years: 2024 – Seattle, WA ..................................

AADA hosts 10th annual Capitol Hill Skin Cancer Check and Health Fair

Moving the needle ... By Apoorva Stull, Senior Manager, Advocacy Communications, May 1, 2024 DermWorld ... breaks down the latest highlights of AADA advocacy activities at the federal and state legislative and regulatory level. On May 15, the AADA hosted its 10th annual Capitol Hill Skin Cancer Check and Health

2024 AAD Innovation Academy | Official exhibitor suppliers

Experient) is the official housing provider for the 2024 AAD Innovation Academy Meeting in Seattle, WA

Herpes zoster, immunosuppression, and vaccination: Far from a blistering pace

By Warren R. Heymann, MD July 5, 2016 Do you recognize the name Chris Gueffroy? He was the last person shot trying to escape from East Berlin, before the wall came down. I had long promised myself that I would get Zostavax when I turned 60. Now 61, I am

Advocacy Update Feb. 4 2025

IN THIS ISSUE / Feb. 4, 2025 Physician champions introduce Medicare physician payment fix in House Academy joins coalition urging less regulatory burdens in Medicare Advantage and Part D program AADA urges CMS to improve MVP framework Become an AADA Advocacy Key Contact Support dermatology champions in Congress through SkinPAC

Advocacy Update Dec 9, 2025

IN THIS ISSUE / Dec. 9, 2025 AADA endorses annual inflationary update to Medicare payment legislation Upcoming formulary prior authorization changes to Blue Cross Blue Shield’s federal employee coverage Podcast highlights advocacy on dermatopathology payer and regulatory challenges AMA offering $1 million in community health program grants Peter Friedman, MD,

Taking the challenge: Social media, adolescents, and the skin

By Albert C. Yan, MD June 12, 2019 Vol. 1, No. 14 Patterned skin injury can raise the specter of non-accidental trauma. However, over the past decade or so, striking examples of patterned skin injury have emerged among adolescents and pre-teens that share certain features: these are self-induced voluntarily; the

Coming to an ICU Near You — Candida auris

By Warren R. Heymann, MD ... Nov. 30, 2017 ... I first became aware of Candida auris (C. auris) during my 96-year-old mother’s most recent hospitalization in New York for congestive heart failure. The infectious disease epidemiologist called to ask permission to swab my mother’s skin for the yeast,

Advocacy Update Feb. 18 2025

IN THIS ISSUE / Feb. 18, 2025 AADA, house of medicine demand reversal of Medicare cut and provide a pay boost AADA highlights need for Medicare physician payment reform at House Committee on Ways and Means hearing Dermatology addresses new CLIA requirements for lab directors Legislators reject pharmacists’ effort to

Advocacy Update Mar. 18, 2025

IN THIS ISSUE / Mar. 18, 2025 AADA outraged that Congress passed government funding without doc fix AADA advocates for dermatologists in CLIA lab director requirements FDA testing confirms minimal benzene in most benzoyl peroxide acne products, some voluntary recalls issued Add your voice and become an AADA Advocacy Key

Slammed by slime

By Warren R. Heymann, MD Sept. 16, 2020 Vol. 2, No. 37 Visiting Nickelodeon Studios in Orlando, Florida in the early 1990s was a religious experience for my family. Watching a live recording of ... Double Dare, my daughters were fervently praying to be among the chosen few to be

Prior authorization audits and innovations: Are we finally reducing the (PA)in?

By Lorraine L. Rosamilia, MD, FAAD Aug. 9, 2023 Vol. 5, No. 32 There is little utility in defining prior authorization (PA) for prescription medications as it relates to the practice of dermatology, as each of us navigates this process and its stagnation every day. There have been several studies

PDF of Histiocytosis

Kornik RI, Naik HB, Lee CC, Estrada-Veras J, Gahl WA, Cowen EW.

Glucose monitors: Not as sweet as they seem

By Christen M. Mowad, MD Oct. 9, 2019 Vol. 1, No. 31 ... The next contact allergen of the year has been announced early by the American Contact Dermatitis Society and it is an acrylate, isobornyl acrylate. (1) This chemical is a photopolymerizable monomer that has been used in industrial

A medal-worthy diagnosis: Medallion-like dermal dendrocyte hamartoma

By Warren R. Heymann, MD, FAAD Aug. 30, 2023 Vol. 5, No. 35 A personal joy of dermatology is rendering a diagnosis in a lesion or rash that I have only read about but never previously encountered in practice. Beyond being intellectually satisfying, having a precise diagnosis is reassuring, as

Preferentially expressed antigen in melanoma (PRAME)

By Jason B. Lee, MD, FAAD May 10, 2023 Vol. 5, No. 19 In 1980, the discovery of S100 protein expression in cultured metastatic melanoma cell lines (1) stirred excitement in the pathology community for its potential role as a diagnostic marker for melanoma. The excitement was short-lived once it

Researching therapeutic reformation of the capillary malformation: Arteriovenous Malformation Syndrome

By Warren R. Heymann, MD June 17, 2020 Vol. 2, No. 24 Small cutaneous lesions may have profound systemic implications. Astute dermatologists will recognize these lesions and assess patients accordingly, often to the surprise of referring physicians and patients alike. ... The Capillary Malformation – Arteriovenous Malformation (CM-AVM) syndrome was

PDF of the Academy position on Vitamin D

Lyon: World Health Organization. 11 Nnoham KE, Clarke A.

Time to reassess messing around with steroids and psoriasis

By Warren R. Heymann, MD March 3, 2021 Vol. 3, No. 9 You don't tug on Superman ’ ... s cape You don't spit into the wind You don't pull the mask off that old Lone Ranger And you don't mess around with Jim If the late Jim Croce was

Cannabis arteritis: Getting higher on the differential diagnosis list of ulcerative lesions

DermWorld Insights and Inquiries ... By Warren R. Heymann, MD, FAAD, January 1, 2026 Vol. 8, No. 1 Marijuana use is on the rise. In 2022, nearly 22% of people had used the drug in the past year, with steep increases in the number of people 65 and older who

Saving face: The importance of recognizing facial discoid dermatosis

By Warren R. Heymann, MD, FAAD Feb. 22, 2023 Vol. 5, No. 8 I get excited when astute dermatologists describe and label dermatoses that I have seen but could not adequately diagnose. Two recent examples include acute inflammatory edema and alpha-gal syndrome. I (and presumably you too) have encountered patients

Adding protothecosis to the protocol

By Warren R. Heymann, MD, FAAD April 23, 2025 Vol. 7, No. 16 As a dermatology resident at the outset of the AIDS epidemic, I quickly learned that all bets are off when diagnosing infectious diseases in immunocompromised hosts. That experience taught me to culture broadly for bacterial, atypical mycobacterial,

2020 Legislative Conference Overview of Asks

Suzan DelBene, D-WA, Mike Kelly, R-PA, Ami Bera, MD, D-CA, and Roger Marshall, MD, R-KS.

Complications of silicone injections: persistence, stigma, and treatment

By Howa Yeung, MD, MSc, FAAD Jan. 18, 2023 Vol. 5, No. 3 Walking in with a cane and reporting his severe skin pain, a patient of mine recalled travelling with their friend to get buttock injections in a hotel room in another state over a decade ago. ... The

2024 AAD Annual Meeting Sponsorship Prospectus

sponsorships are also available for the 2024 AAD Innovation Academy (formerly Summer Meeting) in Seattle, WA

Assessing the significance of a Long-Developed Habit: The role of LDH in dermatology

By Warren R. Heymann, MD, FAAD July 14, 2021 Vol. 3, No. 28 Upon ordering laboratory tests recently for a patient with cutaneous T cell lymphoma, I included a lactate dehydrogenase (LDH) level, as I have done for decades, without giving it much thought. When I came across an article

Propranolol and neutrophilic dermatoses: Can beta-blockade be better blockade?

By Warren R. Heymann, MD, FAAD December 8, 2021 Vol. 3, No. 48 Ask any dermatology resident what the first-line treatment is for infantile hemangiomas (IH) and you will get a matter-of-fact response — "propranolol" — as if this has been an entrenched fact for decades. Barely more than a

The Venetian antithesis: Treating median canaliform nail dystrophy

By Warren R. Heymann, MD, FAAD Oct. 4, 2023 Vol. 5, No. 40 Tony Bennett may have left his heart in San Francisco, but mine remains in Venice. ... (The editorial staff of DWI&I offer our sincerest condolences to the families of those who perished, and our prayers for recovery

Do not get burned by missing Staphylococcal scalded skin syndrome

By Warren Heymann, MD April 28, 2021 Vol. 3, No. 17 I would be surprised if any first-year dermatology resident could not differentiate Staphylococcal scalded skin syndrome (SSSS) from toxic epidermal necrolysis (TEN). What is straightforward now was a source of confusion for decades. The following is an elegant summation

Biotin supplementation for hair and nail health: Does it pass the test?

By Warren R. Heymann, MD, FAAD November 17, 2021 Vol. 3, No. 46 When patients ask me about biotin supplementation for their hair or nails, the usual question is what dose they should take, not whether or not it has any value. High dose over-the-counter biotin supplements (≥ 5 mg/day,

After 23 years, a syndrome converted me into an eflornithine believer

By Warren R. Heymann, MD, FAAD July 12, 2023 Vol. 5, No. 28 I learned that Vaniqa (eflornithine - ... α -difluoromethylornithine [DFMO]) was discontinued. Topical eflornithine was released in 2000 to reduce facial hirsutism. When the drug was released, I recall being fascinated by the premise of its mechanism.

A shot in the dark

By Danielle M. DeHoratius, MD March 10, 2021 Vol. 3, No. 10 Danielle DeHoratius, MD ... For the past few Mondays, I have been asked to see the following "emergency" patients who called in with the diagnosis of cellulitis after the COVID-19 vaccination. Typically, these patients were seen in urgent

Is it a waste for dermatologists to order fecal calprotectin?

By Warren R. Heymann, MD, FAAD June 22, 2022 Vol. 4, No. 25 I am still haunted by my initiation to Crohn disease. My late brother Andrew, who succumbed to the illness because of a confluence of complications at 29 years-old, first manifested symptoms as a child. It was a

The profound dermatological manifestations of COVID-19 Part VI: Going to the dogs

By Warren R. Heymann, MD July 29, 2020 Vol. 2, No. 30 Disclaimers: This commentary was written on July 12, 2020 for a publication date of July 29, 2020. The issues related to the COVID-19 pandemic are changing rapidly. The content included in this commentary may no longer be factual

Dermatologists should not be in the dark about kratom

By Warren R. Heymann, MD, FAAD Oct. 11, 2023 Vol. 5, No. 41 Dermatological sleuthing mandates an ever-expanding knowledge database. The correct diagnosis may prove elusive if you do not know the right questions to ask. Astute clinicians have a differential diagnosis of cutaneous and/or mucosal hyperpigmentation, including heavy metal

March 20, 2023 AAD/A Board of Directors agenda

Resort & Spa, Itasca, IL 2024 Innovation Academy – August 1-4, 2024 (Thurs – Sun) Seattle, WA

Agenda of the July 23, 2022 AAD/A Board of Directors meeting.

600 PM – 9:00 PM (Central) 2024 Innovation Academy Meeting – Seattle, WA

Promising therapeutic developments for cutaneous lupus erythematosus: Interfering with interferon

By Warren R. Heymann, MD, FAAD Aug. 17, 2022 Vol. 4, No. 33 Disfigurement due to scars and dyspigmentation complicating discoid lupus erythematosus (DLE) can be devastating. The cornerstones of therapy for cutaneous lupus erythematosus (CLE) are steroids (topical, intralesional, systemic) and antimalarials (hydroxychloroquine, chloroquine, quinacrine). Secondary agents include immunosuppressive

PS-Chemical Identity of Fragrances

Frosch PJ, Pilz B, Andersen KE, Burrows D, Camarasa JG, Dooms-Goossens A, Ducombs G, Fuchs T, Hannuksela

The nexus of VEXAS syndrome

By Warren R. Heymann, MD, FAAD December 1, 2021 Vol. 3, No. 47 You may not be familiar with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, but it is conceivable that you have already unknowingly encountered patients with the disorder. ... To appreciate the clinical nuances of the VEXAS

AAD Innovation Academy 2020 Technical Exhibitor Prospectus

Friday. 70 Pike St., Seattle, WA 98101 Welcome Reception (Exhibits Open) 3 Thursday, August 13 ......

CXCR4 antagonist therapy based on a WHIM syndrome

By Warren R. Heymann, MD, FAAD June 12, 2024 Vol. 6, No. 24 Emelio* had a delightfully whimsical personality that matched his syndrome’s acronym — WHIM ( ... W arts, ... H ypogammaglobulinemia, ... I nfections, and ... M yelokathexis). His smile was as infectious as his verrucae, and he

Agenda for the Nov. 5, 2022 meeting of the AAD and AADA Board of Directors meetings.

6:00 PM – 9:00 PM (Central) 2024 Innovation Academy Meeting – Seattle, WA

Short anagen syndrome: The long and short of it

By Warren R. Heymann, MD, FAAD Feb. 7, 2024 Vol. 6, No. 6 Have you ever encountered a patient who says that their hair does not grow very much and that they rarely need to cut their hair? I have, and I suppose you have, too. Although considered uncommon, short

Exchanging plasma exchange for a novel approach: The potential of FcRn antagonists in dermatologic autoimmune disease

By Warren R. Heymann, MD, FAAD Nov. 1, 2023 Vol. 5, No. 44 Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are potentially life-threatening disorders demanding aggressive therapy with all the finesse and skill that dermatologists can muster. PV is characterized by IgG autoantibodies targeting desmoglein (Dsg)‐3, which is associated with

Search

Filters

Content Filters

Content Type